The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The NDA filing is supported by results from the phase III evERA Breast Cancer study
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
